A so-called ‘productivity crisis’ has been ascribed to the pharmaceutical research and development industry. Despite increases in investment and funding, this has not corresponded to increases in the approval of novel drugs. Why do so many drugs fail to receive approval, and what other means should we be focusing on for the benefit of patients?
The technological revolution involving artificial intelligence, big data, machine learning and robotics is posed to deeply change healthcare and biomedical research, and things are changing fast. In this rapidly evolving scenario, researchers and health professionals need to acquire new skills and knowledge.